Search Within

Elgilda Musi

Formats
  1. Journal Article (6)
  2. Meeting Abstract (2)
Groups
  1. Melanoma Disease Management Team (5)
  2. Department of Medicine (3)
  3. Solid Tumor Oncology Division (3)
  4. Head and Neck Service (2)
  5. GSK Faculty (1)
  6. Sarcoma Service (1)

More Groups

People
  1. Gary Schwartz (8)
  2. Grazia Ambrosini (6)
  3. Elisa De Stanchina (4)
  4. Alan Ho (2)
  5. Adriana Haimovitz-Friedman (1)
  6. David D'Adamo (1)

More People

Years
  1. 2014 (2)
  2. 2013 (2)
  3. 2012 (2)
  4. 2009 (2)
Publications
  1. Cancer Research (2)
  2. Molecular Cancer Therapeutics (2)
  3. Autophagy (1)
  4. Clinical Cancer Research (1)
  5. Inorganic Chemistry (1)
  6. PLoS ONE (1)
Publishers
  1. American Association for Cancer Research (5)
  2. ACS Publications (1)
  3. Public Library of Science (1)
  4. Taylor & Francis Group (1)

Results (8)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • BIBF1120, an investigational triple angiokinase inhibitor, in combination with inhibitors of mTOR signaling shows potent antitumor activity in preclinical models of sarcoma
    Meeting Abstract

    Patwardhan, P. P.; Musi, E.; Ivy, K. S.; Giovino, N.; Schwartz, G. K.
    Cancer Research (2014)

    Fulltext@MSK | Save
  • The phosphoinositide 3-kinase a selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells
    Journal Article

    Musi, E.; Ambrosini, G.; de Stanchina, E.; Schwartz, G. K.
    Molecular Cancer Therapeutics (2014)

    Fulltext@MSK | Save
  • The parp inhibitor olaparib (AZD2281) greatly enances the effect of temozolomide in soft tissue sarcoma cell lines
    Meeting Abstract

    Musi, E.; Ambrosini, G.; Schwartz, G. K.
    Cancer Research (2013)

    Fulltext@MSK | Save
  • Inhibition of mutant GNAQ signaling in uveal melanoma induces AMPK-dependent autophagic cell death
    Journal Article

    Ambrosini, G.; Musi, E.; Ho, A. L.; de Stanchina, E.; Schwartz, G. K.
    Molecular Cancer Therapeutics (2013)

    Fulltext@MSK | Save
  • Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype
    Journal Article

    Ho, A. L.; Musi, E.; Ambrosini, G.; Nair, J. S.; Deraje Vasudeva, S.; de Stanchina, E.; Schwartz, G. K.
    PLoS ONE (2012)

    Fulltext@MSK | Save
  • The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: Preclinical investigations and results of a phase I dose-escalation clinical trial
    Journal Article

    Luke, J. J.; D'adamo, D. R.; Dickson, M. A.; Keohan, M. L.; Carvajal, R. D.; Maki, R. G.; de Stanchina, E.; Musi, E.; Singer, S.; Schwartz, G. K.
    Clinical Cancer Research (2012)

    Fulltext@MSK | Save
  • Synthesis, characterization, and in vitro antimalarial and antitumor activity of new ruthenium(II) complexes of chloroquine
    Journal Article

    Rajapakse, C. S. K.; Martinez, A.; Naoulou, B.; Jarzecki, A. A.; Suárez, L.; Deregnaucourt, C.; Sinou, V.; Schrével, J.; Musi, E.; Ambrosini, G.; more...
    Inorganic Chemistry (2009)

    Fulltext@MSK | Save
  • Safingol (L-threo-sphinganine) induces autophagy in solid tumor cells through inhibition of PKC and the PI3-kinase pathway
    Journal Article

    Coward, J.; Ambrosini, G.; Musi, E.; Truman, J. P.; Haimovitz-Friedman, A.; Allegood, J. C.; Wang, E.; Merrill, A. H. Jr; Schwartz, G. K.
    Autophagy (2009)

    Fulltext@MSK | Save